|Bid||71.61 x 800|
|Ask||71.85 x 2200|
|Day's range||71.11 - 72.06|
|52-week range||56.56 - 73.34|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||298.88|
|Earnings date||26 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||2.84 (3.96%)|
|Ex-dividend date||14 Sept 2021|
|1y target est||75.99|
Gilead Sciences (GILD) closed at $70.96 in the latest trading session, marking a -0.91% move from the prior day.
Suzanne Judd, Ph.D., Epidemiologist at the University of Alabama at Birmingham School of Public Health, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
FOSTER CITY, Calif., September 20, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s virology research and development programs at the virtual IDWeek 2021 conference, taking place September 29 – October 3. The findings in COVID-19 research, HIV treatment research and HIV prevention research are the latest example of Gilead’s ongoing commitment to help address the evolving COVID-19 pandemic and the needs of people affected by HIV.